Last 12 months
Inside the activity.
0 purchase rows · 31 sale rows
Disclosed non-derivative P/S rows, by transaction month. Includes amendments and private transactions.Monthly counts
| Month | Purchases | Sales |
|---|---|---|
| Nov 2025 | 0 | 5 |
| Dec 2025 | 0 | 4 |
| Jan 2026 | 0 | 4 |
| Feb 2026 | 0 | 4 |
| Mar 2026 | 0 | 3 |
| Apr 2026 | 0 | 3 |
| May 2026 | 0 | 1 |
| Jun 2026 | 0 | 1 |
| Jul 2026 | 0 | 1 |
| Aug 2026 | 0 | 2 |
| Sep 2026 | 0 | 2 |
| Oct 2026 | 0 | 1 |
Latest available
Insider transactions
Purchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Owner / reported role | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| November 27, 2017 Filed Nov 28, 2017 23:27 UTC |
Sodhi RajwantPresident, SaaS Business
|
Tax withholdingResMed Common Stock | 1,153 | $84.63 | $97,578.39 |
DisclosureSEC source: 0001140361-17-044016 · doc1.xml · nonDerivative · entry 2 Sodhi Rajwant · CIK 0001715325 · President, SaaS Business 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 28,434 F3 · shares: Disposition to issuer for tax withholding on vesting of performance-based Restricted Stock Units granted on 11/19/2014. Read SEC document |
| November 27, 2017 Filed Nov 28, 2017 23:27 UTC |
Sodhi RajwantPresident, SaaS Business
|
GrantResMed Common Stock | 3,066 | $84.63 | $259,475.58 |
DisclosureSEC source: 0001140361-17-044016 · doc1.xml · nonDerivative · entry 1 Sodhi Rajwant · CIK 0001715325 · President, SaaS Business 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 29,587 F1 · kind: Shares acquired on vesting of performance-based restricted stock units. The PSUs were granted November 19, 2014, with a three-year performance period. The shares were earned and vested November 27, 2017, when the ResMed compensation committee certified performance. F2 · shares: Shares earned based on performance at 57% of the target award. Read SEC document |
| November 27, 2017 Filed Nov 28, 2017 23:26 UTC |
Farrell Michael J.Chief Executive Officer
|
Tax withholdingResMed Common Stock | 14,546 | $84.63 | $1,231,027.98 |
DisclosureSEC source: 0001140361-17-044015 · doc1.xml · nonDerivative · entry 2 Farrell Michael J. · CIK 0001485164 · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 224,395 F3 · shares: Disposition to issuer for tax withholding on vesting of performance-based Restricted Stock Units granted on 11/19/2014. Read SEC document |
| November 27, 2017 Filed Nov 28, 2017 23:26 UTC |
Farrell Michael J.Chief Executive Officer
|
GrantResMed Common Stock | 27,876 | $84.63 | $2,359,145.88 |
DisclosureSEC source: 0001140361-17-044015 · doc1.xml · nonDerivative · entry 1 Farrell Michael J. · CIK 0001485164 · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 238,941 F1 · kind: Shares acquired on vesting of performance-based restricted stock units. The PSUs were granted November 19, 2014, with a three-year performance period. The shares were earned and vested November 27, 2017, when the ResMed compensation committee certified performance. F2 · shares: Shares earned based on performance at 57% of the target award. Read SEC document |
| November 27, 2017 Filed Nov 28, 2017 23:26 UTC |
Douglas Robert AndrewPresident and COO ResMed Inc.
|
Tax withholdingResMed Common Stock | 9,513 | $84.63 | $805,085.19 |
DisclosureSEC source: 0001140361-17-044014 · doc1.xml · nonDerivative · entry 2 Douglas Robert Andrew · CIK 0001352232 · President and COO ResMed Inc. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 62,507 F3 · shares: Disposition to issuer for tax withholding on vesting of performance-based Restricted Stock Units granted on 11/19/2014. Read SEC document |
| November 27, 2017 Filed Nov 28, 2017 23:26 UTC |
Douglas Robert AndrewPresident and COO ResMed Inc.
|
GrantResMed Common Stock | 18,231 | $84.63 | $1,542,889.53 |
DisclosureSEC source: 0001140361-17-044014 · doc1.xml · nonDerivative · entry 1 Douglas Robert Andrew · CIK 0001352232 · President and COO ResMed Inc. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 72,020 F1 · kind: Shares acquired on vesting of performance-based restricted stock units. The PSUs were granted November 19, 2014, with a three-year performance period. The shares were earned and vested November 27, 2017, when the ResMed compensation committee certified performance. F2 · shares: Shares earned based on performance at 57% of the target award. Read SEC document |
| November 27, 2017 Filed Nov 29, 2017 17:20 UTC |
McHale RichardPresident, RC Business
|
Tax withholdingResMed Common Stock | 1,331 | $84.63 | $112,642.53 |
DisclosureSEC source: 0001140361-17-044075 · doc1.xml · nonDerivative · entry 2 McHale Richard · CIK 0001715326 · President, RC Business 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 14,204 F3 · shares: Disposition to issuer for tax withholding on vesting of performance-based Restricted Stock Units granted on 11/19/2014. Read SEC document |
| November 27, 2017 Filed Nov 29, 2017 17:20 UTC |
McHale RichardPresident, RC Business
|
GrantResMed Common Stock | 3,540 | $84.63 | $299,590.20 |
DisclosureSEC source: 0001140361-17-044075 · doc1.xml · nonDerivative · entry 1 McHale Richard · CIK 0001715326 · President, RC Business 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,535 F1 · kind: Shares acquired on vesting of performance-based restricted stock units. The PSUs were granted November 19, 2014, with a three-year performance period. The shares were earned and vested November 27, 2017, when the ResMed compensation committee certified performance. F2 · shares: Shares earned based on performance at 57% of the target award. Read SEC document |
| November 27, 2017 Filed Dec 18, 2017 21:17 UTC Amendment |
Sodhi RajwantPresident, SaaS Business
|
Tax withholdingResMed Common Stock | 1,600 | $84.63 | $135,408.00 |
DisclosureSEC source: 0001140361-17-046501 · doc1.xml · nonDerivative · entry 2 Sodhi Rajwant · CIK 0001715325 · President, SaaS Business 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 26,556 F3 · shares: Disposition to issuer for tax withholding on vesting of performance-based Restricted Stock Units granted on 11/19/2014. F4 · shares: Amendment to adjust netted shares at the correct tax rate. Read SEC document |
| November 27, 2017 Filed Dec 18, 2017 21:17 UTC Amendment |
Sodhi RajwantPresident, SaaS Business
|
GrantResMed Common Stock | 3,066 | $84.63 | $259,475.58 |
DisclosureSEC source: 0001140361-17-046501 · doc1.xml · nonDerivative · entry 1 Sodhi Rajwant · CIK 0001715325 · President, SaaS Business 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 29,587 F1 · kind: Shares acquired on vesting of performance-based restricted stock units. The PSUs were granted November 19, 2014, with a three-year performance period. The shares were earned and vested November 27, 2017, when the ResMed compensation committee certified performance. F2 · shares: Shares earned based on performance at 57% of the target award. Read SEC document |
| November 20, 2017 Filed Nov 22, 2017 15:48 UTC |
Hollingshead JamesPresident, Sleep Business
|
Exercise / conversionResMed Common Stock Options · Derivative | 7,019 | $0.00 Strike: $43.63 | $0.00 |
DisclosureSEC source: 0001140361-17-043629 · doc1.xml · derivative · entry 3 Hollingshead James · CIK 0001570610 · President, Sleep Business 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: ResMed Commmon Stock · 7,019 shares Expires 2020-03-01 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: Represents date options first become exercisable. Options vest 1/3 annually each November 11. Read SEC document |
| November 20, 2017 Filed Nov 22, 2017 15:48 UTC |
Hollingshead JamesPresident, Sleep Business
|
SaleResMed Common Stock | 7,019 | $84.16 | $590,719.04 |
DisclosureSEC source: 0001140361-17-043629 · doc1.xml · nonDerivative · entry 2 Hollingshead James · CIK 0001570610 · President, Sleep Business 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 59,390 F1 · price: This transaction was executed in multiple trades at prices ranging from $83.74 to $84.53. The price reported above reflects the weighted average sale price. Read SEC document |
| November 20, 2017 Filed Nov 22, 2017 15:48 UTC |
Hollingshead JamesPresident, Sleep Business
|
Exercise / conversionResMed Common Stock | 7,019 | $43.63 | $306,238.97 |
DisclosureSEC source: 0001140361-17-043629 · doc1.xml · nonDerivative · entry 1 Hollingshead James · CIK 0001570610 · President, Sleep Business 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 66,409 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| November 16, 2017 Filed Nov 18, 2017 02:46 UTC |
PACE GARY WDirector
|
GrantResMed Common Stock | 2,991 | $0.00 | $0.00 |
DisclosureSEC source: 0001140361-17-043281 · doc1.xml · nonDerivative · entry 1 PACE GARY W · CIK 0001184778 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 100,578 F1 · shares: Shares awarded represent Restricted Stock Units. The RSUs cliff vest on the earlier of 11/11/2018, or the annual shareholder's meeting in the year following the grant date. Read SEC document |
| November 16, 2017 Filed Nov 18, 2017 02:04 UTC |
FARRELL PETER CDirector
|
GrantResMed Common Stock | 2,991 | $84.98 | $254,175.18 |
DisclosureSEC source: 0001140361-17-043277 · doc1.xml · nonDerivative · entry 1 FARRELL PETER C · CIK 0001186102 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 295,933 F1 · shares: Shares awarded represent Restricted Stock Units. The RSUs cliff vest on the earlier of 11/11/2018, or the annual shareholder's meeting in the year following the grant date. Read SEC document |
| November 16, 2017 Filed Nov 20, 2017 19:03 UTC |
TAYLOR RONALD RDirector
|
GrantResMed Common Stock | 2,991 | $0.00 | $0.00 |
DisclosureSEC source: 0001140361-17-043348 · doc1.xml · nonDerivative · entry 1 TAYLOR RONALD R · CIK 0001161920 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 26,636 F1 · shares: Shares awarded represent Restricted Stock Units. The RSUs cliff vest on the earlier of 11/11/2018, or the annual shareholder's meeting in the year following the grant date. Read SEC document |
| November 16, 2017 Filed Nov 20, 2017 18:56 UTC |
PENDARVIS DAVIDChief Administrative Officer
|
GrantResMed Common Stock Options · Derivative | 25,695 | $0.00 Strike: $84.98 | $0.00 |
DisclosureSEC source: 0001140361-17-043347 · doc1.xml · derivative · entry 2 PENDARVIS DAVID · CIK 0001196723 · Chief Administrative Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 25,695 Underlying: ResMed Common Stock · 25,695 shares Expires 2024-11-16 F1 · derivative.exercise_date: Represents date options first become exercisable. Options vest 1/3 annually each November 11, 2018, 2019 and 2020. Read SEC document |
| November 16, 2017 Filed Nov 20, 2017 18:55 UTC |
Douglas Robert AndrewPresident and COO ResMed Inc.
|
GrantResMed Common Stock Options · Derivative | 68,017 | $0.00 Strike: $84.98 | $0.00 |
DisclosureSEC source: 0001140361-17-043346 · doc1.xml · derivative · entry 3 Douglas Robert Andrew · CIK 0001352232 · President and COO ResMed Inc. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 68,017 Underlying: ResMed Commmon Stock · 68,017 shares Expires 2024-11-19 F1 · derivative.exercise_date: Represents date options first become exercisable. Options vest 1/3 annually each November 11, 2018, 2019 and 2020. Read SEC document |
| November 16, 2017 Filed Nov 20, 2017 18:54 UTC |
SULPIZIO RICHARDDirector
|
GrantResMed Common Stock | 2,991 | $0.00 | $0.00 |
DisclosureSEC source: 0001140361-17-043345 · doc1.xml · nonDerivative · entry 1 SULPIZIO RICHARD · CIK 0001191329 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,420 F1 · shares: Shares awarded are restricted stock units. The RSUs cliff vest on the earlier of November 11, 2018, or the annual shareholder's meeting in the year following the grant date. Read SEC document |
| November 16, 2017 Filed Nov 20, 2017 18:53 UTC |
Farrell Michael J.Chief Executive Officer
|
GrantResMed Common Stock Options · Derivative | 102,781 | $0.00 Strike: $84.98 | $0.00 |
DisclosureSEC source: 0001140361-17-043343 · doc1.xml · derivative · entry 2 Farrell Michael J. · CIK 0001485164 · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 102,781 Underlying: ResMed Common Stock · 102,781 shares Expires 2024-11-16 F1 · derivative.exercise_date: Represents date options first become exercisable. Options vest 1/3 annually each November 11, 2018, 2019 and 2020. Read SEC document |
| November 16, 2017 Filed Nov 20, 2017 18:50 UTC |
WAREHAM JOHN PDirector
|
GrantResMed Common Stock Options · Derivative | 15,115 | $0.00 Strike: $84.98 | $0.00 |
DisclosureSEC source: 0001140361-17-043340 · doc1.xml · derivative · entry 2 WAREHAM JOHN P · CIK 0001231182 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,115 Underlying: ResMed Commmon Stock · 15,115 shares Expires 2024-11-16 F1 · derivative.exercise_date: Options vest in full (i) on the first Nov. 11 following the grant date or (ii) the first annual shareholders meeting following grant date. Read SEC document |
| November 16, 2017 Filed Nov 20, 2017 18:49 UTC |
Burt CarolDirector
|
GrantResMed Common Stock | 2,991 | $0.00 | $0.00 |
DisclosureSEC source: 0001140361-17-043339 · doc1.xml · nonDerivative · entry 1 Burt Carol · CIK 0001493926 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 21,640 F1 · shares: Shares awarded are restricted stock units. The RSUs cliff vest on the earlier of November 11, 2018, or the annual shareholder's meeting in the year following the grant date. Read SEC document |
| November 10, 2017 Filed Nov 13, 2017 22:42 UTC |
FARRELL PETER CDirector
|
Tax withholdingResMed Common Stock | 1,858 | $83.06 | $154,325.48 |
DisclosureSEC source: 0001140361-17-042207 · doc1.xml · nonDerivative · entry 9 FARRELL PETER C · CIK 0001186102 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 292,942 F5 · shares: Disposition to issuer for tax withholding on vesting of performance-based Restricted Stock Units granted on 11/16/2016. Read SEC document |
| November 10, 2017 Filed Nov 14, 2017 23:59 UTC |
McHale RichardPresident, RC Business
|
Tax withholdingResMed Common Stock | 909 | $83.06 | $75,501.54 |
DisclosureSEC source: 0001140361-17-042904 · doc1.xml · nonDerivative · entry 2 McHale Richard · CIK 0001715326 · President, RC Business 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 11,995 F3 · shares: Disposition to issuer for tax withholding on vesting of performance-based Restricted Stock Units granted on 11/19/2014. Read SEC document |
| November 10, 2017 Filed Nov 14, 2017 23:59 UTC |
McHale RichardPresident, RC Business
|
Tax withholdingResMed Common Stock | 794 | $83.06 | $65,949.64 |
DisclosureSEC source: 0001140361-17-042904 · doc1.xml · nonDerivative · entry 1 McHale Richard · CIK 0001715326 · President, RC Business 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 12,904 F1 · shares: Disposition to issuer for tax withholding on vesting of performance-based Restricted Stock Units granted on 11/16/2016. F2 · balance_after: Includes 177 shares of ResMed stock purchased on October 31, 2017, through the ResMed Employee Stock Purchase Plan. Read SEC document |
| November 10, 2017 Filed Nov 14, 2017 23:31 UTC |
Sodhi RajwantPresident, SaaS Business
|
Tax withholdingResMed Common Stock | 361 | $83.06 | $29,984.66 |
DisclosureSEC source: 0001140361-17-042897 · doc1.xml · nonDerivative · entry 4 Sodhi Rajwant · CIK 0001715325 · President, SaaS Business 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 26,521 F6 · shares: Disposition to issuer for tax withholding on vesting of performance-based Restricted Stock Units granted on 12/16/2013. Read SEC document |
| November 10, 2017 Filed Nov 14, 2017 23:31 UTC |
Sodhi RajwantPresident, SaaS Business
|
Tax withholdingResMed Common Stock | 1,363 | $83.06 | $113,210.78 |
DisclosureSEC source: 0001140361-17-042897 · doc1.xml · nonDerivative · entry 3 Sodhi Rajwant · CIK 0001715325 · President, SaaS Business 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 26,882 F5 · shares: Disposition to issuer for tax withholding on vesting of performance-based Restricted Stock Units granted on 11/16/2016. Read SEC document |
| November 10, 2017 Filed Nov 14, 2017 23:31 UTC |
Sodhi RajwantPresident, SaaS Business
|
Tax withholdingResMed Common Stock | 1,227 | $83.06 | $101,914.62 |
DisclosureSEC source: 0001140361-17-042897 · doc1.xml · nonDerivative · entry 2 Sodhi Rajwant · CIK 0001715325 · President, SaaS Business 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 28,245 F4 · shares: Disposition to issuer for tax withholding on vesting of performance-based Restricted Stock Units granted on 11/19/2015. Read SEC document |
| November 10, 2017 Filed Nov 14, 2017 23:31 UTC |
Sodhi RajwantPresident, SaaS Business
|
Tax withholdingResMed Common Stock | 688 | $83.06 | $57,145.28 |
DisclosureSEC source: 0001140361-17-042897 · doc1.xml · nonDerivative · entry 1 Sodhi Rajwant · CIK 0001715325 · President, SaaS Business 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 29,472 F1 · shares: Disposition to issuer for tax withholding on vesting of performance-based Restricted Stock Units granted on 11/19/2014. F2 · balance_after: Includes 152 shares of ResMed stock purchased on October 31, 2017, through the ResMed Employee Stock Purchase Plan. F3 · balance_after: Corrects misstatement of shares reported. Certified outstanding shares totaled 6,528 for grant issued 11/19/2015 prior 16-b officer status. Read SEC document |
| November 10, 2017 Filed Nov 14, 2017 20:55 UTC |
PENDARVIS DAVIDChief Administrative Officer
|
Tax withholdingResMed Common Stock | 1,262 | $83.06 | $104,821.72 |
DisclosureSEC source: 0001140361-17-042712 · doc1.xml · nonDerivative · entry 3 PENDARVIS DAVID · CIK 0001196723 · Chief Administrative Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 90,788 F3 · shares: Disposition to issuer for tax withholding on vesting of performance-based Restricted Stock Units granted on 11/16/2016. Read SEC document |
| November 10, 2017 Filed Nov 14, 2017 20:55 UTC |
PENDARVIS DAVIDChief Administrative Officer
|
Tax withholdingResMed Common Stock | 1,140 | $83.06 | $94,688.40 |
DisclosureSEC source: 0001140361-17-042712 · doc1.xml · nonDerivative · entry 2 PENDARVIS DAVID · CIK 0001196723 · Chief Administrative Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 92,050 F2 · shares: Disposition to issuer for tax withholding on vesting of performance-based Restricted Stock Units granted on 11/19/2015. Read SEC document |
| November 10, 2017 Filed Nov 14, 2017 20:55 UTC |
PENDARVIS DAVIDChief Administrative Officer
|
Tax withholdingResMed Common Stock | 1,194 | $83.06 | $99,173.64 |
DisclosureSEC source: 0001140361-17-042712 · doc1.xml · nonDerivative · entry 1 PENDARVIS DAVID · CIK 0001196723 · Chief Administrative Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 93,190 F1 · shares: Disposition to issuer for tax withholding on vesting of performance-based Restricted Stock Units granted on 11/19/2014. Read SEC document |
| November 10, 2017 Filed Nov 14, 2017 20:53 UTC |
Farrell Michael J.Chief Executive Officer
|
Tax withholdingResMed Common Stock | 4,732 | $83.06 | $393,039.92 |
DisclosureSEC source: 0001140361-17-042706 · doc1.xml · nonDerivative · entry 3 Farrell Michael J. · CIK 0001485164 · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 211,065 F4 · shares: Disposition to issuer for tax withholding on vesting of performance-based Restricted Stock Units granted on 11/16/2016. Read SEC document |
| November 10, 2017 Filed Nov 14, 2017 20:53 UTC |
Farrell Michael J.Chief Executive Officer
|
Tax withholdingResMed Common Stock | 8,518 | $83.06 | $707,505.08 |
DisclosureSEC source: 0001140361-17-042706 · doc1.xml · nonDerivative · entry 2 Farrell Michael J. · CIK 0001485164 · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 215,797 F3 · shares: Disposition to issuer for tax withholding on vesting of performance-based Restricted Stock Units granted on 11/19/2015. Read SEC document |
| November 10, 2017 Filed Nov 14, 2017 20:53 UTC |
Farrell Michael J.Chief Executive Officer
|
Tax withholdingResMed Common Stock | 8,684 | $83.06 | $721,293.04 |
DisclosureSEC source: 0001140361-17-042706 · doc1.xml · nonDerivative · entry 1 Farrell Michael J. · CIK 0001485164 · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 224,315 F1 · shares: Disposition to issuer for tax withholding on vesting of performance-based Restricted Stock Units granted on 11/19/2014. F2 · balance_after: Includes 267 shares of ResMed stock purchased on Oct 31, 2017, through the ResMed Employee Stock Purchase Plan Read SEC document |
| November 10, 2017 Filed Nov 14, 2017 20:54 UTC |
Hollingshead JamesPresident, Americas
|
Tax withholdingResMed Common Stock | 2,523 | $83.06 | $209,560.38 |
DisclosureSEC source: 0001140361-17-042708 · doc1.xml · nonDerivative · entry 3 Hollingshead James · CIK 0001570610 · President, Americas 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 59,390 F4 · shares: Disposition to issuer for tax withholding on vesting of performance-based Restricted Stock Units granted on 11/16/2016. Read SEC document |
| November 10, 2017 Filed Nov 14, 2017 20:54 UTC |
Hollingshead JamesPresident, Americas
|
Tax withholdingResMed Common Stock | 1,186 | $83.06 | $98,509.16 |
DisclosureSEC source: 0001140361-17-042708 · doc1.xml · nonDerivative · entry 2 Hollingshead James · CIK 0001570610 · President, Americas 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 61,913 F3 · shares: Disposition to issuer for tax withholding on vesting of performance-based Restricted Stock Units granted on 11/19/2015. Read SEC document |
| November 10, 2017 Filed Nov 14, 2017 20:54 UTC |
Hollingshead JamesPresident, Americas
|
Tax withholdingResMed Common Stock | 2,483 | $83.06 | $206,237.98 |
DisclosureSEC source: 0001140361-17-042708 · doc1.xml · nonDerivative · entry 1 Hollingshead James · CIK 0001570610 · President, Americas 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 63,099 F1 · shares: Disposition to issuer for tax withholding on vesting of performance-based Restricted Stock Units granted on 11/19/2014. F2 · balance_after: Includes 111 shares of ResMed stock purchased on October 31, 2017, through the ResMed Employee Stock Purchase Plan. Read SEC document |
| November 10, 2017 Filed Nov 14, 2017 20:51 UTC |
Douglas Robert AndrewPresident and COO ResMed Inc.
|
Tax withholdingResMed Common Stock | 6,309 | $83.06 | $524,025.54 |
DisclosureSEC source: 0001140361-17-042704 · doc1.xml · nonDerivative · entry 2 Douglas Robert Andrew · CIK 0001352232 · President and COO ResMed Inc. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 53,789 F3 · shares: Disposition to issuer for tax withholding on vesting of performance-based Restricted Stock Units granted on 11/16/2016. Read SEC document |
| November 10, 2017 Filed Nov 14, 2017 20:51 UTC |
Douglas Robert AndrewPresident and COO ResMed Inc.
|
Tax withholdingResMed Common Stock | 5,680 | $83.06 | $471,780.80 |
DisclosureSEC source: 0001140361-17-042704 · doc1.xml · nonDerivative · entry 1 Douglas Robert Andrew · CIK 0001352232 · President and COO ResMed Inc. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 60,098 F1 · shares: Disposition to issuer for tax withholding on vesting of performance-based Restricted Stock Units granted on 11/19/2014. F2 · balance_after: Includes 177 shares of ResMed stock purchased on October 31, 2017, through the ResMed Employee Stock Purchase Plan. Read SEC document |
| November 10, 2017 Filed Dec 18, 2017 21:16 UTC Amendment |
Sodhi RajwantPresident, SaaS Business
|
Tax withholdingResMed Common Stock | 518 | $83.06 | $43,025.08 |
DisclosureSEC source: 0001140361-17-046500 · doc1.xml · nonDerivative · entry 4 Sodhi Rajwant · CIK 0001715325 · President, SaaS Business 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 25,090 F6 · shares: Disposition to issuer for tax withholding on vesting of performance-based Restricted Stock Units granted on 12/16/2013. F7 · shares: Amendment adjusts for netted shares using the correct tax rate. Read SEC document |
| November 10, 2017 Filed Dec 18, 2017 21:16 UTC Amendment |
Sodhi RajwantPresident, SaaS Business
|
Tax withholdingResMed Common Stock | 1,893 | $83.06 | $157,232.58 |
DisclosureSEC source: 0001140361-17-046500 · doc1.xml · nonDerivative · entry 3 Sodhi Rajwant · CIK 0001715325 · President, SaaS Business 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 25,608 F5 · shares: Disposition to issuer for tax withholding on vesting of performance-based Restricted Stock Units granted on 11/16/2016. F7 · shares: Amendment adjusts for netted shares using the correct tax rate. Read SEC document |
| November 10, 2017 Filed Dec 18, 2017 21:16 UTC Amendment |
Sodhi RajwantPresident, SaaS Business
|
Tax withholdingResMed Common Stock | 1,704 | $83.06 | $141,534.24 |
DisclosureSEC source: 0001140361-17-046500 · doc1.xml · nonDerivative · entry 2 Sodhi Rajwant · CIK 0001715325 · President, SaaS Business 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 27,501 F4 · shares: Disposition to issuer for tax withholding on vesting of performance-based Restricted Stock Units granted on 11/19/2015. F7 · shares: Amendment adjusts for netted shares using the correct tax rate. Read SEC document |
| November 10, 2017 Filed Dec 18, 2017 21:16 UTC Amendment |
Sodhi RajwantPresident, SaaS Business
|
Tax withholdingResMed Common Stock | 955 | $83.06 | $79,322.30 |
DisclosureSEC source: 0001140361-17-046500 · doc1.xml · nonDerivative · entry 1 Sodhi Rajwant · CIK 0001715325 · President, SaaS Business 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 29,205 F1 · shares: Disposition to issuer for tax withholding on vesting of performance-based Restricted Stock Units granted on 11/19/2014. F7 · shares: Amendment adjusts for netted shares using the correct tax rate. F2 · balance_after: Includes 152 shares of ResMed stock purchased on October 31, 2017, through the ResMed Employee Stock Purchase Plan. F3 · balance_after: Corrects misstatement of shares reported. Certified outstanding shares totaled 6,528 for grant issued 11/19/2015 prior 16-b officer status. Read SEC document |
| November 09, 2017 Filed Nov 13, 2017 22:42 UTC |
FARRELL PETER CDirector
|
Exercise / conversionResmed Stock Option Plan · Derivative | 82,460 | $0.00 Strike: $27.58 | $0.00 |
DisclosureSEC source: 0001140361-17-042207 · doc1.xml · derivative · entry 13 FARRELL PETER C · CIK 0001186102 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: ResMed Common Stock · 82,460 shares Expires 2018-11-16 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F6 · derivative.exercise_date: Represents date options first became exercisable. Options vested 1/4 per year. Read SEC document |
| November 09, 2017 Filed Nov 13, 2017 22:42 UTC |
FARRELL PETER CDirector
|
Exercise / conversionResmed Stock Option Plan · Derivative | 3,625 | $0.00 Strike: $27.58 | $0.00 |
DisclosureSEC source: 0001140361-17-042207 · doc1.xml · derivative · entry 12 FARRELL PETER C · CIK 0001186102 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: ResMed Common Stock · 3,625 shares Expires 2018-11-16 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F6 · derivative.exercise_date: Represents date options first became exercisable. Options vested 1/4 per year. Read SEC document |
| November 09, 2017 Filed Nov 13, 2017 22:42 UTC |
FARRELL PETER CDirector
|
Exercise / conversionResmed Stock Option Plan · Derivative | 20,492 | $0.00 Strike: $58.24 | $0.00 |
DisclosureSEC source: 0001140361-17-042207 · doc1.xml · derivative · entry 11 FARRELL PETER C · CIK 0001186102 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: ResMed Common Stock · 20,492 shares Expires 2022-11-19 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F6 · derivative.exercise_date: Represents date options first became exercisable. Options vested 1/4 per year. Read SEC document |
| November 09, 2017 Filed Nov 13, 2017 22:42 UTC |
FARRELL PETER CDirector
|
Exercise / conversionResmed Stock Option Plan · Derivative | 11,815 | $0.00 Strike: $52.02 | $0.00 |
DisclosureSEC source: 0001140361-17-042207 · doc1.xml · derivative · entry 10 FARRELL PETER C · CIK 0001186102 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: ResMed Common Stock · 11,815 shares Expires 2021-11-19 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F6 · derivative.exercise_date: Represents date options first became exercisable. Options vested 1/4 per year. Read SEC document |
| November 09, 2017 Filed Nov 13, 2017 22:42 UTC |
FARRELL PETER CDirector
|
SaleResMed Common Stock | 82,460 | $82.70 | $6,819,442.00 |
DisclosureSEC source: 0001140361-17-042207 · doc1.xml · nonDerivative · entry 8 FARRELL PETER C · CIK 0001186102 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 294,800 F4 · price: This transaction was executed in multiple trades at prices ranging from 82.49 to 82.89. The price reported above represents the weighted average sales price. Read SEC document |
| November 09, 2017 Filed Nov 13, 2017 22:42 UTC |
FARRELL PETER CDirector
|
SaleResMed Common Stock | 3,625 | $82.69 | $299,751.25 |
DisclosureSEC source: 0001140361-17-042207 · doc1.xml · nonDerivative · entry 7 FARRELL PETER C · CIK 0001186102 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 377,260 F3 · price: This transaction was executed in multiple trades at prices ranging from $82.51 to $82.82. The price reported above reflects the weighted average sale price. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.